We are live on !
Find out more
Rhenman & Partners Asset Management Portfolio holdings
AUM
$1.06B
Turnover
25.47%
1-Year Est. Return
52.03%
This Fund
S&P 500
This Quarter Est. Return
+22.03%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$1.06B
AUM Growth
+$249M
(+31%)
Cap. Flow
+$137M
Cap. Flow % of AUM
Cap. Flow %
12.89%
Top 10 Holdings %
Top 10 Hldgs %
25.08%
Holding
106
New
20
Increased
41
Reduced
34
Closed
7
Avg Time Held
2.8
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$28.5M |
| 2 |
Merck
MRK
|
+$25M |
| 3 |
UnitedHealth
UNH
|
+$17.8M |
| 4 |
Johnson & Johnson
JNJ
|
+$16.9M |
| 5 |
Centene
CNC
|
+$13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$14.1M |
| 2 |
Eli Lilly
LLY
|
+$11.6M |
| 3 |
Veeva Systems
VEEV
|
+$11.2M |
| 4 |
Adaptive Biotechnologies
ADPT
|
+$10M |
| 5 |
Boston Scientific
BSX
|
+$9.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$361B
| $38.9M | 3.67% |
93,600
+48,100
| +106% | +$17.8M |
2013 Q4
50 quarters
|
|
2
CVS Health
CVS
$115B
| $28.9M | 2.73% |
279,374
-57,126
| -17% | -$5.1M |
2024 Q3
7 quarters
|
|
|
3
AstraZeneca
AZN
$288B
| $28.5M | 2.69% |
+151,500
| New | +$28.5M |
2026 Q2
0 quarters
|
|
|
4
Merck
MRK
$363B
| $27.4M | 2.59% |
+213,500
| New | +$25M |
2026 Q2
0 quarters
|
|
|
5
Eli Lilly
LLY
$1.28T
| $26.8M | 2.53% |
22,315
-11,400
| -34% | -$11.6M |
2023 Q2
12 quarters
|
|
6
AbbVie
ABBV
$521B
| $24.4M | 2.3% |
96,775
+25,200
| +35% | +$5.42M |
2019 Q3
27 quarters
|
|
7
Alignment Healthcare
ALHC
$1.61B
| $23.7M | 2.24% |
997,083
-56,367
| -5% | -$1.08M |
2022 Q3
15 quarters
|
|
8
Edwards Lifesciences
EW
$60.8B
| $23.5M | 2.22% |
260,000
+97,000
| +60% | +$8.13M |
2025 Q2
4 quarters
|
|
9
Gilead Sciences
GILD
$211B
| $22.5M | 2.13% |
178,250
+10,500
| +6% | +$1.38M |
2020 Q2
24 quarters
|
|
10
Jazz Pharmaceuticals
JAZZ
$15.9B
| $21.1M | 1.99% |
87,440
+11,550
| +15% | +$2.53M |
2014 Q3
47 quarters
|
|
11
Biogen
BIIB
$37.5B
| $20.5M | 1.93% |
94,850
-14,250
| -13% | -$2.73M |
2022 Q3
15 quarters
|
|
12
Stryker
SYK
$121B
| $20.5M | 1.93% |
65,000
+17,200
| +36% | +$5.42M |
2026 Q1
1 quarter
|
|
|
13
Boston Scientific
BSX
$65.4B
| $19.2M | 1.81% |
450,500
-174,500
| -28% | -$9.48M |
2017 Q3
35 quarters
|
|
|
14
Johnson & Johnson
JNJ
$675B
| $18.4M | 1.74% |
+72,500
| New | +$16.9M |
2026 Q2
0 quarters
|
|
15
Guardant Health
GH
$20.9B
| $17.3M | 1.63% |
115,000
-30,000
| -21% | -$3.26M |
2025 Q3
3 quarters
|
|
|
16
Regeneron Pharmaceuticals
REGN
$99.2B
| $17.1M | 1.61% |
27,390
-20,710
| -43% | -$14.1M |
2022 Q1
17 quarters
|
|
17
Glaukos
GKOS
$14.6B
| $16.6M | 1.57% |
119,000
+35,000
| +42% | +$4.43M |
2016 Q2
40 quarters
|
|
18
BioMarin Pharmaceuticals
BMRN
$11.3B
| $16.6M | 1.57% |
290,500
+83,500
| +40% | +$4.57M |
2013 Q4
50 quarters
|
|
19
Nurix Therapeutics
NRIX
$1.78B
| $16.6M | 1.57% |
684,250
+370,750
| +118% | +$6.32M |
2024 Q2
8 quarters
|
|
20
Natera
NTRA
$46.4B
| $16.6M | 1.56% |
61,050
+9,450
| +18% | +$2.01M |
2022 Q3
15 quarters
|
|
21
Mirum Pharmaceuticals
MIRM
$6.18B
| $16.3M | 1.54% |
139,205
+46,600
| +50% | +$4.68M |
2024 Q1
9 quarters
|
|
22
Insmed
INSM
$26.5B
| $16.2M | 1.53% |
151,960
-7,800
| -5% | -$944K |
2024 Q2
8 quarters
|
|
23
Tenet Healthcare
THC
$23.3B
| $15.9M | 1.5% |
85,200
+31,200
| +58% | +$5.74M |
2021 Q2
20 quarters
|
|
24
Thermo Fisher Scientific
TMO
$266B
| $15.8M | 1.49% |
31,580
-9,760
| -24% | -$4.69M |
2020 Q1
25 quarters
|
|
|
25
Centene
CNC
$34.9B
| $15.7M | 1.48% |
+244,000
| New | +$13M |
2026 Q2
0 quarters
|
|
Similar funds
BDP
Rhenman & Partners Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, Rhenman & Partners Asset Management held 106 positions worth $1.06B, up 31% from $810M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Rhenman & Partners Asset Management deployed $137M of net new capital in Q2 2026, opening 20 new positions and adding to 41 existing holdings. Its largest new stake was AstraZeneca: 151,500 shares worth $28.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $14.1M trimmed.
- Rhenman & Partners Asset Management's largest Q2 2026 buy was AstraZeneca: 151,500 shares worth $28.5M.
- Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2026, an estimated $17.8M increase.
- Rhenman & Partners Asset Management's biggest Q2 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.1M.
- Rhenman & Partners Asset Management fully exited Adaptive Biotechnologies in Q2 2026, selling an estimated $10M.
- Rhenman & Partners Asset Management's ten largest holdings make up 25% of its $1.06B portfolio in Q2 2026.
- Rhenman & Partners Asset Management opened 20 new positions and closed 7 in Q2 2026.
- Rhenman & Partners Asset Management's portfolio value rose 31% quarter-over-quarter to $1.06B.
Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.